Samidorphan: Discovery of a Medication to Treat Central Nervous System Disorders

At Rensselaer Polytechnic Institute, the main goal of Mark Wentland's research group is to design, synthesize and characterize oral, long-acting modulators of opioid G protein-coupled receptors (GPCRs) as medications to treat cocaine abuse and other central nervous system disorders in humans.

A common structural feature of a large number of opioids is a phenolic-OH group (see prototypic opioid pharmacophore below) that plays a crucial role in molecular recognition via H-bonding to a histidine residue of a mu opioid GPCR. For many opioids, however, this OH group is responsible for poor oral bioavailability and/or short half-life via O-glucuronidation.

In 2001, we published the first report that a carboxamide group (CONH₂) was an effective replacement for this prototypic phenolic-OH group of opioids. In addition to high affinity binding to opioid GPCRs, certain carboxamido-substituted opioids have much improved pharmacokinetic properties (relative to their phenolic-OH counterparts) as a consequence of high metabolic stability. Since 2001 our research group has focused on capitalizing on this discovery to achieve our main goal. Our first-generation opioid modulator in this series was 8-carboxamidocyclazocine (8-CAC). Subsequent optimization of 8-CAC provided the mu-antagonist, samidorphan. Samidorphan first appeared in the scientific literature in 2005. Our publications describing these discoveries as well as a wealth of structure-activity relationship data are cataloged in PubMed.

![Prototypic opioid pharmacophore](image1.png)
![8-CAC](image2.png)
![Samidorphan](image3.png)

In 2006, Rensselaer signed a license agreement granting Alkermes Inc., exclusive rights to a library of opioid compounds discovered by our team. Alkermes has subsequently sponsored multiple Phase 1, 2 and 3 clinical trials involving the use of samidorphan to treat CNS disorders. Two combination medications containing samidorphan are currently in late-stage development - ALKS 5461 (samidorphan in combination with buprenorphine) and ALKS 3831 (samidorphan in combination with olanzapine) have potential for treating patients with major depressive disorder and schizophrenia, respectively. The following press releases from Alkermes provide additional information:

**Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application**

**Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia**
In addition to samidorphan, other compounds from Rensselaer’s patent estate that have entered clinical trials are ALKS 37, ALKS 7106 and ALKS 7119.

Collaborators for our opioid GPCR modulator research program are:

- Dr. Jean Bidlack and coworkers at the University of Rochester
- Discovery and development personnel at Alkermes, Inc.

Acknowledgments: This research was supported by the National Institute of Drug Abuse of the National Institutes of Health under award numbers DA12180 and KO5-DA00360. Funding from AMRI, Inc. is also gratefully acknowledged.